<DOC>
	<DOCNO>NCT01675089</DOCNO>
	<brief_summary>The purpose study determine whether zolendronic acid , third generation bisphosphonate , effective prevent bone loss first year kidney transplantation .</brief_summary>
	<brief_title>Zoledronic Acid Prevent Bone Loss After Kidney Transplantation</brief_title>
	<detailed_description>For treatment osteoporosis general population , number drug reduce BMD ( bone mineral density ) loss rate incident fracture . For instance , bisphosphonates improve BMD , reduce hip fracture rate decrease mortality post-menopausal woman . Because lack data safety increase risk adverse effect , use drug controversial patient chronic kidney disease ( CKD ) abnormalities PTH vitamin D , estimate glomerular filtration rate ( GFR ) less 30 ml/min/1.73m² ( CKD stag 4 5 ) transplantation . The efficacy short long term bisphosphonate treatment kidney transplantation examine ; however , histomorphometric fracture rate reduction data lacking . The purpose study determine whether zolendronic acid , third generation bisphosphonate , effective prevent bone loss first year kidney transplantation .</detailed_description>
	<mesh_term>Renal Osteodystrophy</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>All adult kidney transplant recipient stable perioperative able return regular followup Glomerular filtration rate &lt; 30 ml/min/1.73m² one week transplantation Previous parathyroidectomy diagnosis adynamic bone disease ( bone biopsy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>bone disease</keyword>
	<keyword>kidney transplantation</keyword>
	<keyword>bisphosphonates</keyword>
</DOC>